Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.
暂无分享,去创建一个
E. Giannoni | L. Magnelli | S. Bombardieri | A. Laurenzana | P. Chiarugi | B. Kahaleh | L. Bazzichi | S. Serratì | F. Margheri | A. Chillà | G. Fibbi | J. Dotor | E. Feijoó | M. Del Rosso
[1] L. Magnelli,et al. Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. , 2011, Blood.
[2] A. Leask. Possible strategies for anti-fibrotic drug intervention in scleroderma , 2011, Journal of Cell Communication and Signaling.
[3] Michael L Whitfield,et al. The pathogenesis of systemic sclerosis. , 2011, Annual review of pathology.
[4] S. Bombardieri,et al. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. , 2010, Arthritis and rheumatism.
[5] M. Trojanowska. Noncanonical transforming growth factor β signaling in scleroderma fibrosis , 2009, Current opinion in rheumatology.
[6] M. T. Grande,et al. Fibroblast activation and myofibroblast generation in obstructive nephropathy , 2009, Nature Reviews Nephrology.
[7] P. Chiarugi,et al. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. , 2009, Cancer research.
[8] A. Albini,et al. TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. , 2009, Biochemical pharmacology.
[9] D. Abraham,et al. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? , 2008, Rheumatology.
[10] D. Abraham,et al. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. , 2008, Cytokine & growth factor reviews.
[11] J. Prieto,et al. Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. , 2007, Cytokine.
[12] D. Nosi,et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. , 2006, Arthritis and rheumatism.
[13] S. Bombardieri,et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptor , 2006, The Journal of pathology.
[14] H. Steinbrenner,et al. Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species , 2006, Journal of Cell Science.
[15] D. Abraham,et al. Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.
[16] B. Giusti,et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. , 2005, Arthritis and rheumatism.
[17] Jiri Zavadil,et al. TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.
[18] D. Yamazaki,et al. Regulation of cancer cell motility through actin reorganization , 2005, Cancer science.
[19] M. Cinelli,et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.
[20] Andrew Leask,et al. TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] P. Friedl. Prespecification and plasticity: shifting mechanisms of cell migration. , 2004, Current opinion in cell biology.
[22] D. Abraham,et al. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. , 2003, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[23] P. Friedl,et al. Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.
[24] P. Greenwel,et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. , 2003, Cytokine.
[25] A. Strongin,et al. Compensation mechanism in tumor cell migration , 2003, The Journal of cell biology.
[26] E. Robertis,et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β , 2002, Nature Cell Biology.
[27] M. Takigawa,et al. Role and interaction of connective tissue growth factor with transforming growth factor‐β in persistent fibrosis: A mouse fibrosis model , 1999, Journal of cellular physiology.
[28] T. Matsumura,et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. , 1999, Journal of biochemistry.
[29] S. Milani,et al. Functions of the fibrinolytic system in human ito cells and its control by basic fibroblast and platelet‐derived growth factor , 1999, Hepatology.
[30] E. Leroy. SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .
[31] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[32] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[33] Ying E Zhang,et al. Non-Smad pathways in TGF-β signaling , 2009, Cell Research.
[34] X. Chevalier,et al. Nerve root pain secondary to posterior articular cysts: a report of 6 cases and review of the literature. , 1992, Clinical and experimental rheumatology.